1Negro A, Martelletti P. Patient selection for migraine preventive treatment with anti-CGRP(r) monoclonal antibodies. Expert Rev Neurother. 2019;19(8):769-776. https://doi.org/10.1080/14737175.2019.1621749
2Schoenen J, Manise M, Nonis R, et al. Monoclonal antibodies blocking CGRP transmission: an update on their added value in migraine prevention. Rev Neurol. 2020;176(10):788-803. https://doi.org/10.1016/j.neurol.2020.04.027
3Raffaelli B, Neeb L, Reuter U. Monoclonal antibodies for the prevention of migraine. Expert Opin Biol Ther. 2019;19(12):1307-1317. https://doi.org/10.1080/14712598.2019.1671350
4Ahmed Z, Hogue O, Lee M, et al. Calcitonin gene related peptide monoclonal antibodies in the treatment of migraine: is there a difference in efficacy between inhibitors of the ligand compared to inhibitors of the receptor? Headache. 2020;60(S1):4. 62nd Annual Scientific Meeting American Headache Society abstract. https://doi.org/10.1111/head.13854
5Dodick DW. CGRP ligand and receptor monoclonal antibodies for migraine prevention: evidence review and clinical implications. Cephalalgia. 2019;39(3):445-458. https://doi.org/10.1177/0333102418821662
6Data on file, Eli Lilly and Company and/or one of its subsidiaries.
7Zhu Y, Liu Y, Zhao J, et al. The efficacy and safety of calcitonin gene-related peptide monoclonal antibody for episodic migraine: a meta-analysis. Neurol Sci. 2018;39(12):2097–2106. https://doi.org/10.1007/s10072-018-3547-3